Researchers from the Wake Forest Institute for Regenerative Medicine (WFIRM) have determined a new way to deliver DNA editing tools so that the presence of their proteins in cells is reduced, in what they have called a “hit and run” approach.
Scientists have used synthetic nucleotides to double the traditional number of life’s building blocks to eight.
Roche is set to pay $4.3bn for the acquisition of Spark Therapeutics, a gene therapy company that will put the pharma giant ahead in one of the biggest growing markets around.
A combination of immunotherapy drug avelumab and targeted agent axitinib has been seen to increases progression-free survival in patients with metastatic kidney cancer, scientists from the Dana-Farber Institute have reported following a phase 3 clinical trial.
D4: Pharma is a highly-select gathering of 80-100 very senior and experienced pharma professionals responsible for making important decisions, as well as turning innovation and new ideas into measurable progress.
Global life science researcher Bio-Rad has announced that its droplet digital PCR-based test for chronic myeloid leukaemia (CML), the first of its kind, has been cleared by the FDA. The test quantifies BCR-ABL, the gene fusion which causes CML, in the blood.
TEXLab, a mathematical AI software created by scientists at Imperial College London and the University of Melbourne can predict survival rates of patients with ovarian cancer more accurately than any current method, a trial published in Nature Communications has found.
Sperm which lives longer before fertilising an egg produces more health children, Uppsala University and University of East Anglia (UEA) scientists have found.
The leading advisor for the UK science and technology (S&T) sectors has estimated that despite Brexit, Cambridge and Oxford’s S&T companies will require 2.5 million more square feet of lab and research space over the next five years, and are looking to accommodate 20,000 new R&D workers by 2023.
Esketamine, a Johnson & Johnson antidepressant based on the party drug ketamine, has received backing from an FDA independent advisory group.
Toxic antibody tisutumab vedotin (TV) has shown promise as a treatment for a number of types of advanced cancer. This “trojan horse” approach has now reached the stage of being tested on a wider variety of patients. Institute of Cancer Research and Royal Marsden NHS Foundation Trust researchers tested the drug on 147 patients to evaluate potential benefits and side effects.
Johnson and Johnson has vowed to become the first pharmaceutical giant to add its medicine prices to television adverts, starting in March 2018. The company said it will list not only product price before rebates or discounts, as well as potential out-of-pocket costs which patients will pay.
Genomics England, NHS England and The Royal Society are holding a scientific meeting at the Royal Society in Carlton House Terrace to celebrate the successful conclusion of the 100,000 Genomes Project, which was declared finished in December last year.
The Pistoia Alliance, a global not-for-profit company working in life sciences R&D, has announced the launch of the next phase in its ongoing blockchain project. The next phase includes a workshop on 12 March 2019 open to both members and non-members which will look to develop several potential use cases to the proof-of-concept stage. It will also identify which blockchain applications will have no industry value.
More errors occur in DNA replication during times of stress when resources are scares, scientists at the University of Toronto have found.